Oncogenes and cancer

New England Journal of Medicine

Volumn 358, Issue 5, 2008, Pages 502-511

  Croce, Carlo M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APC; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SU 5412; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT1 PROTEIN;

ANGIOGENESIS; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CHORDOMA; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE FUSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR CLONING; ONCOGENE; PRIORITY JOURNAL; REVIEW; STEM CELL; TUMOR GROWTH; UPREGULATION;

EID: 38749114995     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra072367     Document Type: Review

References (70)

1. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-4.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 1985;315:550-4.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
4. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-71.
5. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-8.
6. Croce CM, Shander M, Martinis J, et al. Chromosomal location of the genes for human immunoglobulin heavy chain. Proc Natl Acad Sci U S A 1979;76:3416-9.
7. Erikson J, Martinis J, Croce CM. Assignment of the genes for human lambda immunoglobulin chains to chromosome 22. Nature 1981;294:173-5.
8. Dalla Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982;79:7824-7.
9. Croce CM, Thierfelder W, Erikson J, et al. Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt lymphoma. Proc Natl Acad Sci U S A 1983;80:6922-6.
10. Erikson J, Nishikura K, ar-Rushdi A, et al. Translocation of an immunoglobulin kappa locus to a region 3? of an unrearranged c-myc oncogene enhances c-myc transcription. Proc Natl Acad Sci U S A 1983;80:7581-5.
11. ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce CM. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science 1983;222:390-3.
12. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV. Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 1983;302:33-7.
13. McCoy MS, Toole JJ, Cunningham JM, Chang EH, Lowy DR, Weinberg RA. Characterization of a human colon/lung carcinoma oncogene. Nature 1983;302:79-81.
14. Tsujimoto Y, Yunis J, Onorato-Showe L, Nowell PC, Croce CM. Molecular cloning of the chromosomal breakpoint of B cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984;224:1403-6.
15. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-3.
16. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8.
17. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 1986;45:485-95.
18. Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte ON. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci U S A 1985;82:1810-4.
19. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-3.
20. Finger LR, Harvey RC, Moore RCA, Showe LC, Croce CM. A common mechanism of chromosomal translocation in T- and B-cell neoplasia. Science 1986;234:982-5.
21. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-400.
22. Idem. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4(5):E131-E136.
23. Croce CM. Role of chromosome translocations in human neoplasia. Cell 1987;49:155-6.
24. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
25. Peterson CL, Workman JL. Promoter targeting and chromatin remodeling by the SWI/SNF complex. Curr Opin Genet Dev 2000;10:187-92.
26. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80.
27. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.
28. Nakamura T, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002;10:1119-28.
29. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316.
30. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
31. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-23.
32. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7:Suppl 4:31-9.
33. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001;33:451-5.
34. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294-9.
35. Pawson T, Warner N. Oncogenic rewiring of cellular signaling pathways. Oncogene 2007;26:1268-75.
36. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997;385:602-9.
37. Kaziro Y, Itoh H, Kozasa T, Nakafuku M, Satoh T. Structure and function of signal-transducing GTP-binding proteins. Annu Rev Biochem 1991;60:349-400.
38. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998; 16:1207-17.
39. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 1986;83:5214-8.
40. Tsujimoto Y, Ikegaki N, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 1987;2:3-7.
41. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
42. Bishop JM. Molecular themes in oncogenesis. Cell 1991;44:235-48.
43. Rodenhuis S. ras And human tumors. Semin Cancer Biol 1992;3:241-7.
44. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 1999;17:1071-9.
45. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
46. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-40.
47. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 1978;253:1357-70.
48. Cowell JK. Double minutes and homogeneously staining regions: gene amplification in mammalian cells. Annu Rev Genet 1982;16:21-59.
49. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-6.
50. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
51. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
52. Ohta M, Inoue H, Cotticelli MG, et al. The human FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated translocation breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
53. Huebner K, Croce CM. FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 2001;1:214-21.
54. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1084-6.
55. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
56. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer 2004;101:2086-97.
57. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science 1998;279:1547-51.
58. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002;108:165-70.
59. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-9.
60. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
61. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
62. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801. [Erratum, N Engl J Med 2006;355:533.]
63. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
64. Volinia S, Calin GA, Liu C-G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
65. Nakamura T, Canaani E, Croce CM. Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing. Proc Natl Acad Sci U S A 2007;104:10980-5.
66. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005;102:3627-32.
67. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006;103:7024-9.
68. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 micro-RNA family. Cell 2005;120:635-47.
69. Cimmino A, Calin GA, Fabbri M, et al. miR-15 And miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102:13944-9. [Erratum, Proc Natl Acad Sci U S A 2006;103:2464.]
70. Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29.